{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:29Z","timestamp":1740126809704,"version":"3.37.3"},"reference-count":52,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adrenocortical carcinoma (ACC) is a rare but very aggressive endocrine malignancy with poor survival. Histopathology is important for diagnosis, while in some cases immunohistochemical markers and gene profiling of the resected tumor may be superior to current staging systems to determine prognosis. We aimed to present the 20-year experience at a tertiary hospital in patients with ACCs and correlate the immunohistochemical characteristics of ACCs with the clinical and morphological characteristics of the tumors and the survival of the patients. Forty-five patients with ACC were included in the study. All the resections were R0. The tumor size and weight, the disease stage (ENSAT classification), Weiss score and Helsinki score were examined along with immunohistochemical expression of inhibin-A, melan A, calretinin, Ki67, synaptophysin, p53, vimentin, CKAE1\/AE3. The male to female ratio was 1:1.37. The median age at diagnosis was 55.5 years (IQR 19\u201377). The median size of ACCs was 9\u2009cm (IQR 3.5\u201322\u2009cm) and the median weight 127\u2009g (IQR 18\u20131400\u2009g). The median follow up period was 18 months (IQR 1\u201396). Ki67 varied from&lt;1% to 75% (median: 16.4%). The expression of melan-A and lower expression of Ki-67 (\u22644) were independently associated with longer OS time (p=0.01 and p=0.04, respectively). In multivariable analysis, tumor volume&gt;400\u2009cm3 (p=0.046), Weiss score&gt;5 (p=0.007) and overexpression of p53 (p=0.036) were independent risk factors for shorter survival. Adrenocortical carcinoma is a rare and very aggressive endocrine malignancy. The most important factors that determine long-term prognosis of ACC are the disease stage at diagnosis, the Weiss score, and the Ki67 index. Immunohistochemical markers such as melan A could also serve as prognostic factors.<\/jats:p>","DOI":"10.1055\/a-1666-9026","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T23:59:36Z","timestamp":1636156776000},"page":"709-716","source":"Crossref","is-referenced-by-count":3,"title":["Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes"],"prefix":"10.1055","volume":"53","author":[{"given":"George","family":"Zografos","sequence":"first","affiliation":[{"name":"Department of Surgery, General Hospital of Athens \u201cG. Gennimatas\u201d, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kassi","sequence":"first","affiliation":[{"name":"Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Unit of Endocrinology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, National & Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Parianos","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Surgery, General Hospital of Athens \u201cG. Gennimatas\u201d, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kyriakopoulos","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Pathology, Evaggelismos Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis D.","family":"Kostakis","sequence":"additional","affiliation":[{"name":"Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Royal Free Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-693X","authenticated-orcid":false,"given":"Narjes","family":"Nasiri-Ansari","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysanthi","family":"Aggeli","sequence":"additional","affiliation":[{"name":"Department of Surgery, General Hospital of Athens \u201cG. Gennimatas\u201d, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Dimitriadi","sequence":"additional","affiliation":[{"name":"Department of Pathology, General Hospital of Athens \u201cG. Gennimatas\u201d, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, First Department of Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Kaltsas","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, National & Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors","volume":"113","author":"K Y Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress?","volume":"30","author":"E Kebebew","year":"2006","journal-title":"World J Surg"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12957-015-0527-4","article-title":"Diagnostic and prognostic features in adrenocortical carcinoma: A single institution case series and review of the literature","volume":"13","author":"K N Wanis","year":"2015","journal-title":"World J Surg Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma \u2013 towards genomics guided clinical care","volume":"15","author":"J Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"M Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1530\/EJE-11-0693","article-title":"Serum inhibin pro-alphaC is a tumor marker for adrenocortical carcinomas","volume":"166","author":"J Hofland","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","article-title":"Clinical review: Adrenocortical carcinoma: Clinical update","volume":"91","author":"B Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"M Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"M Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1530\/EJE-10-1147","article-title":"AME position statement on adrenal incidentaloma","volume":"164","author":"M Terzolo","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1677\/JME-09-0143","article-title":"Adrenocortical development and cancer: focus on SF-1","volume":"44","author":"E Lalli","year":"2010","journal-title":"J Mol Endocrinol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.09.035","article-title":"Validation of the prognostic role of the \u201cHelsinki Score\u201d in 225 cases of adrenocortical carcinoma","volume":"62","author":"E Duregon","year":"2017","journal-title":"Hum Pathol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1530\/EJE-18-0027","article-title":"Management of endocrine disease: Adrenocortical carcinoma: Differentiating the good from the poor prognosis tumors","volume":"178","author":"A Jouinot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"A Berruti","year":"2012","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","article-title":"The European network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation","volume":"46","author":"G Lughezzani","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"M Fassnacht","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","first-page":"196","article-title":"Laparoscopic surgery for malignant adrenal tumors","volume":"13","author":"G N Zografos","year":"2009","journal-title":"JSLS"},{"key":"ref18","first-page":"5575","article-title":"Prevalence and prognostic value of lymph node dissection in treating adrenocortical carcinoma: A national experience","volume":"35","author":"S Alanee","year":"2015","journal-title":"Anticancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1245\/s10434-007-9360-5","article-title":"Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data","volume":"14","author":"J E Gervasoni","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"ref20","first-page":"11","article-title":"The role of immunohistochemical markers for the diagnosis and prognosis of adrenocortical neoplasms","author":"A Angelousi","year":"2021","journal-title":"J Pers Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"M Kobel","year":"2016","journal-title":"J Pathol Clin Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2005.03.139","article-title":"Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer","volume":"23","author":"Y C Wang","year":"2005","journal-title":"J Clin Oncol"},{"volume-title":"Current issues in the diagnosis and management of adrenocortical carcinomas. In: Feingold KR, Anawalt B, Boyce A et al. (Eds). Endotext","year":"2000","author":"A Angelousi","key":"ref23"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"A K Lam","year":"2017","journal-title":"Endocr Pathol"},{"volume-title":"Adrenocortical carcinoma. In: Feingold KR, Anawalt B, Boyce A et al. (Eds). Endotext","year":"2000","author":"A Angelousi","key":"ref25"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004048","article-title":"A modern assessment of cancer risk in adrenal incidentalomas: Analysis of 2219 patients","author":"B Kahramangil","year":"2020","journal-title":"Ann Surg"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12020-019-01918-9","article-title":"Adrenocortical carcinoma: Presentation and outcome of a contemporary patient series","volume":"65","author":"I Kostiainen","year":"2019","journal-title":"Endocrine"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015458.2018.1543822","article-title":"Prognostic significance of immunohistochemical markers in adrenocortical carcinoma","volume":"120","author":"L Zlatibor","year":"2020","journal-title":"Acta Chir Belg"},{"key":"ref29","first-page":"15","article-title":"Adrenocortical carcinoma \u2013 a 25 years tertiary centre experience and short review of the literature","volume":"6","author":"J M Nunes","year":"2018","journal-title":"Endocrinol Metab Int J"},{"key":"ref30","first-page":"12","article-title":"Adjuvant therapy in adrenocortical carcinoma: reflections and future directions","author":"S Bedrose","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/his.13255","article-title":"Challenges in surgical pathology of adrenocortical tumours","volume":"72","author":"L A Erickson","year":"2018","journal-title":"Histopathology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1507\/endocrj.K07-079","article-title":"Immunohistochemistry of a proliferation marker Ki67\/MIB1 in adrenocortical carcinomas: Ki67\/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas","volume":"55","author":"R Morimoto","year":"2008","journal-title":"Endocr J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02739705","article-title":"Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 status","volume":"8","author":"A M McNicol","year":"1997","journal-title":"Endocr Pathol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.2002.20.4.941","article-title":"Adrenocortical carcinoma: clinical, morphologic, and molecular characterization","volume":"20","author":"A Stojadinovic","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.humpath.2014.11.015","article-title":"Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas","volume":"46","author":"M Pennanen","year":"2015","journal-title":"Hum Pathol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/PAS.0b013e3182152629","article-title":"Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: A study of 248 cases","volume":"35","author":"A R Sangoi","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/PAI.0b013e31828a96cf","article-title":"Adrenocortical carcinoma: A comprehensive immunohistochemical study of 40 cases","volume":"22","author":"A Weissferdt","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/0973-1482.119329","article-title":"Histopathological study of adrenocortical carcinoma with special reference to the Weiss system and TNM staging and the role of immunohistochemistry to differentiate it from renal cell carcinoma","volume":"9","author":"S K Mondal","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"F Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"A Satelli","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.1038\/ncomms8287","article-title":"Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding","volume":"6","author":"D Perez-Sala","year":"2015","journal-title":"Nat Commun"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12022-017-9482-7","article-title":"A novel TP53 mutation associated with TWIST1 and SIP1 expression in an aggressive adrenocortical carcinoma","volume":"28","author":"D Bulzico","year":"2017","journal-title":"Endocr Pathol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"R Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial-mesenchymal transitions","volume":"119","author":"M Zeisberg","year":"2009","journal-title":"J Clin Invest"},{"key":"ref45","first-page":"13","article-title":"Epithelial and mesenchymal markers in adrenocortical tissues: How mesenchymal are adrenocortical tissues?","author":"I Sbiera","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/1097-0215(20010120)95:1<73::AID-IJC1013>3.0.CO;2-S","article-title":"Expression of Melan-A\/MART-1 antigen as a prognostic factor in primary cutaneous melanoma","volume":"95","author":"M Berset","year":"2001","journal-title":"Int J Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/jso.24665","article-title":"Diagnostic and prognostic role of SF1, IGF2, Ki67, p53, adiponectin, and leptin receptors in human adrenal cortical tumors","volume":"116","author":"A Babinska","year":"2017","journal-title":"J Surg Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"G Assie","year":"2014","journal-title":"Nat Genet"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ccell.2016.07.013","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"30","author":"S Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1210\/jc.2014-3282","article-title":"Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma","volume":"100","author":"C C Juhlin","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication","volume":"103","author":"J Lippert","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00423-011-0868-6","article-title":"Clinical impact of TP53 alterations in drenocortical carcinomas","volume":"397","author":"J Waldmann","year":"2012","journal-title":"Langenbecks Arch Surg"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1666-9026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:17Z","timestamp":1636156817000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1666-9026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,5]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1666-9026","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"type":"print","value":"0018-5043"},{"type":"electronic","value":"1439-4286"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}